PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 14:03:04 2024-06-07 EDT | ||
| 1.61 EUR | -10.06% |
|
| Current month | -36.86% | ||
| 1 month | -46.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 1.61 | -10.06% |
| 24-06-06 | 1.79 | -18.64% |
| 24-06-04 | 2.2 | -10.93% |
| 24-06-03 | 2.47 | -3.14% |
| 24-05-31 | 2.55 | -0.78% |
Real-time Boerse Frankfurt Warrants
Last update June 07, 2024 at 02:03 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1XA1 |
| ISIN | DE000VD1XA13 |
| Date issued | 2024-03-08 |
| Strike | 1,110 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.83 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.72 € |
|---|---|
| Lowest since issue | 1.61 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Certificates
- Certificat
